Hims & Hers surges as Eli Lilly agrees to sell weight-loss drugs directly on its platform
Hims & Hers surges as Eli Lilly agrees to sell weight-loss drugs directly on its platform
Hims & Hers surges as Eli Lilly agrees to sell weight-loss drugs directly on its platform
Key points
اہم نکات
मुख्य बातें
- Eli Lilly has struck a deal to sell its weight-loss drugs Zepbound and Foundayo directly through telehealth platform Hims & Hers, sending the telehealth company's shares up more than 7% in premarket trading, Reuters reports.
- Patients previously had to leave the Hims & Hers site and buy through Lilly's own LillyDirect platform.
- Under the deal, Hims & Hers agreed not to sell compounded copies of Lilly's medicines, and self-pay prices start at $149 a month for the Foundayo pill and $299 for injectable Zepbound.
- Eli Lilly has struck a deal to sell its weight-loss drugs Zepbound and Foundayo directly through telehealth platform Hims & Hers, sending the telehealth company's shares up more than 7% in premarket trading, Reuters reports.
- Patients previously had to leave the Hims & Hers site and buy through Lilly's own LillyDirect platform.
- Under the deal, Hims & Hers agreed not to sell compounded copies of Lilly's medicines, and self-pay prices start at $149 a month for the Foundayo pill and $299 for injectable Zepbound.
- Eli Lilly has struck a deal to sell its weight-loss drugs Zepbound and Foundayo directly through telehealth platform Hims & Hers, sending the telehealth company's shares up more than 7% in premarket trading, Reuters reports.
- Patients previously had to leave the Hims & Hers site and buy through Lilly's own LillyDirect platform.
- Under the deal, Hims & Hers agreed not to sell compounded copies of Lilly's medicines, and self-pay prices start at $149 a month for the Foundayo pill and $299 for injectable Zepbound.
Eli Lilly has struck a deal to sell its weight-loss drugs Zepbound and Foundayo directly through telehealth platform Hims & Hers, sending the telehealth company's shares up more than 7% in premarket trading, Reuters reports. Patients previously had to leave the Hims & Hers site and buy through Lilly's own LillyDirect platform. Under the deal, Hims & Hers agreed not to sell compounded copies of Lilly's medicines, and self-pay prices start at $149 a month for the Foundayo pill and $299 for injectable Zepbound. The move puts Lilly on equal footing with rival Novo Nordisk, which has sold its Wegovy and Ozempic through Hims & Hers since March.
Eli Lilly has struck a deal to sell its weight-loss drugs Zepbound and Foundayo directly through telehealth platform Hims & Hers, sending the telehealth company's shares up more than 7% in premarket trading, Reuters reports. Patients previously had to leave the Hims & Hers site and buy through Lilly's own LillyDirect platform. Under the deal, Hims & Hers agreed not to sell compounded copies of Lilly's medicines, and self-pay prices start at $149 a month for the Foundayo pill and $299 for injectable Zepbound. The move puts Lilly on equal footing with rival Novo Nordisk, which has sold its Wegovy and Ozempic through Hims & Hers since March.
Eli Lilly has struck a deal to sell its weight-loss drugs Zepbound and Foundayo directly through telehealth platform Hims & Hers, sending the telehealth company's shares up more than 7% in premarket trading, Reuters reports. Patients previously had to leave the Hims & Hers site and buy through Lilly's own LillyDirect platform. Under the deal, Hims & Hers agreed not to sell compounded copies of Lilly's medicines, and self-pay prices start at $149 a month for the Foundayo pill and $299 for injectable Zepbound. The move puts Lilly on equal footing with rival Novo Nordisk, which has sold its Wegovy and Ozempic through Hims & Hers since March.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।